| Company Name: |
Spectrum Chemical Manufacturing Corp.
|
| Tel: |
021-021-021-67601398-809-809-809 15221380277 |
| Email: |
marketing_china@spectrumchemical.com |
| Products Intro: |
Product Name:Tyrphostin AG 957
Package:1MG Remarks:T3315
|
|
| Product Name: | AG 957 | | Synonyms: | Lavendustin C Analog, Methyl-4-[N-(2μ,5μ-dihydroxybenzyl)amino]benzoate;NSC 654705;TYRPHOSTIN 957;TYRPHOSTIN AG 957;AG 957;4-AMINO-N-(2,5-DIHYDROXYBENZYL)METHYL BENZOATE;LAVENDUSTIN C ANALOG;METHYL-4-[N-(2',5'-DIHYDROXYBENZYL)AMINO]BENZOATE | | CAS: | 140674-76-6 | | MF: | C15H15NO4 | | MW: | 273.28 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | AG 957 Chemical Properties |
| Boiling point | 504.2±45.0 °C(Predicted) | | density | 1.337±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMSO: soluble | | form | crystalline solid | | pka | 10.30±0.43(Predicted) | | color | Off-white to light brown |
| | AG 957 Usage And Synthesis |
| Description | Tyrphostins are tyrosine phosphorylation inhibitors that act by inhibiting tyrosine kinases. AG957 is a tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 μM, respectively, for human proteins). It also inhibits epidermal growth factor receptor (IC50 = 0.25 μM). As the constitutively-active 210 kDa Bcr-Abl fusion protein commonly occurs in chronic myelogenous leukemia (CML) cells, AG957 is commonly used to study Bcr-Abl signaling in the CML K562 cell line. AG957 is also used to study signaling through c-Abl. | | Uses | Tyrphostin AG 957 is a potent tyrosine kinase inhibitor. Also, it causes metabolic alterations in K562 cells. It is a COVID19-related research product. | | Definition | ChEBI: 4-[(2,5-dihydroxyphenyl)methylamino]benzoic acid methyl ester is an aromatic amine. | | references | [1]. anafi m, gazit a, gilon c, et al. selective interactions of transforming and normal abl proteins with atp, tyrosine-copolymer substrates, and tyrphostins. j biol chem. 1992 mar 5;267(7):4518-23.
[2]. kaur g, gazit a, levitzki a, et al. tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in k562 chronic myelogenous leukemia. anticancer drugs. 1994 apr;5(2):213-22.
[3]. jamieson l, carpenter l, biden tj, et al. protein kinase ciota activity is necessary for bcr-abl-mediated resistance to drug-induced apoptosis. j biol chem. 1999 feb 12;274(7):3927-30.
[4]. fu p, usatyuk pv, lele a, et al. c-abl mediated tyrosine phosphorylation of paxillin regulates lps-induced endothelial dysfunction and lung injury. am j physiol lung cell mol physiol. 2015 may 15;308(10):l1025-38. |
| | AG 957 Preparation Products And Raw materials |
|